Pre-clinical combination of a PARP inhibitor, talazoparib, and carboplatin in triple-negative breast cancer.

被引：0
|
作者：
Cotte, Alexia [1 ]
Beniey, Michele [1 ]
Haque, Takrima [2 ]
Bechir, Nelly [2 ]
Hubert, Audrey [1 ]
Diallo, Korotoum W. [1 ]
Tran-Thanh, Danh [2 ]
Hassan, Saima N. [1 ]
机构：
[1] Univ Montreal, Ctr Rech Univ Montreal CRCHUM, Montreal, PQ H3C 3J7, Canada
[2] Ctr Rech Univ Montreal CRCHUM, Montreal, PQ, Canada
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1066
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Characterization of PARP inhibitor combination therapies in triple-negative breast cancer
    Fyle, Elicia
    Abdesselam, Djihane
    Frederick, Mallory
    Hassan, Saima N.
    CANCER RESEARCH, 2024, 84 (06)
  • [2] Tumor Treating Fields (TTFields) show efficacy in Triple-Negative breast cancer (TNBC) cells alone and in combination with PARP inhibitor Talazoparib
    Ghandali, Maryam
    Srinivasan, Praveen
    Xia, Yutong
    Wong, Eric T.
    Sobol, Robert W.
    Zhou, Lanlan
    Carneiro, Benedito A.
    Graff, Stephanie L.
    El-Deiry, Wafik S.
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Preclinical efficacy of the combination of olaparib plus carboplatin with vandetanib in triple-negative breast cancer.
    Dey, Nandini
    Wu, Hui
    Sun, Yuliang
    De, Pradip
    Leyland-Jones, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer
    Eskiler, G. Guney
    Cecener, G.
    Egeli, U.
    Tunca, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer
    Bardia, A.
    Spring, L. M.
    Juric, D.
    Partridge, A.
    Ligibel, J.
    Kuter, I.
    Peppercorn, J.
    Parsons, H.
    Ryan, P.
    Chawla, D.
    Attaya, V.
    Fitzgerald, D. M.
    Viscosi, E.
    Lormill, B.
    Shellock, M.
    Moy, B.
    Tolaney, S. M.
    Ellisen, L. W.
    ANNALS OF ONCOLOGY, 2020, 31 : S394 - S394
  • [6] Novel pre-clinical model to identify genetic modifiers of triple negative breast cancer.
    Sipe, Laura M.
    Korba, Emily B.
    Lu, Lu
    Williams, Robert W.
    Ashbrook, David G.
    Makowski, Liza
    CANCER RESEARCH, 2021, 81 (13)
  • [7] Pre-clinical activity of the PARP inhibitor AZD2281 in homologous recombination repair deficient triple negative breast cancer
    O'Connor, M. J.
    Lau, A.
    Finn, R. S.
    Knights, C.
    O'Shaughnessy, A.
    Kalous, O.
    Conklin, D.
    Riches, L.
    Carmichael, J.
    Slamon, D. J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 175 - 176
  • [8] A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer
    Paige Baldwin
    Shicheng Yang
    Adrienne Orriols
    Sherrie Wang
    Needa Brown
    Srinivas Sridhar
    Cancer Nanotechnology, 2024, 15
  • [9] Pre-clinical evaluation of single-agent activity of the PARP inhibitor olaparib (AZD2281) in homologous recombination deficient triple-negative breast cancer
    Knights, Charlotte
    Riches, Lucy
    Lau, Alan
    Mangena, Ramu
    Avis, Tim
    Finn, Richard
    O'Shaughnessy, Aisling
    Cranston, Aaron
    Kalous, Ondrej
    Conklin, Dylan
    Carmichael, James
    Slamon, Dennis
    O'Connor, Mark
    CANCER RESEARCH, 2009, 69
  • [10] A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer
    Baldwin, Paige
    Yang, Shicheng
    Orriols, Adrienne
    Wang, Sherrie
    Brown, Needa
    Sridhar, Srinivas
    CANCER NANOTECHNOLOGY, 2024, 15 (01)
12345